


Amendments to the claims:

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

1. (Currently amended): A compound of Formula I:



wherein:

Z is CH[[,]] or CR³ [[or N]]; wherein ~~when Z is CH or CR³; k is 0-4 and when Z is N,~~
~~k is 0-3;~~

p is 0-8;

n is 2-8;

q is 0 or 1;

Q is ~~selected from~~ C₃-C₈ cycloalkyl[[,]] or phenyl, ~~and monocyclic Het~~; wherein said C₃-C₈ cycloalkyl, ~~or phenyl and monocyclic Het~~ are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-CO₂R¹¹, -C₀-C₆ alkyl-C(O)SR¹¹, -C₀-C₆ alkyl-CONR¹²R¹³, -C₀-C₆ alkyl-COR¹⁴, -C₀-C₆ alkyl-NR¹²R¹³, -C₀-C₆ alkyl-SR¹¹, -C₀-C₆ alkyl-OR¹¹, -C₀-C₆ alkyl-SO₃H, -C₀-C₆ alkyl-SO₂NR¹²R¹³, -C₀-C₆ alkyl-SO₂R¹¹, -C₀-C₆ alkyl-SOR¹⁴, -C₀-C₆ alkyl-OCOR¹⁴, -C₀-C₆ alkyl-OC(O)NR¹²R¹³, -C₀-C₆ alkyl-OC(O)OR¹⁴, -C₀-C₆ alkyl-NR¹²C(O)OR¹⁴, -C₀-C₆ alkyl-NR¹²C(O)NR¹²R¹³, and -C₀-C₆ alkyl-NR¹²COR¹⁴, where said C₁-C₆ alkyl is optionally unsubstituted or substituted by one or more halo substituents;

W¹ and W² are each independently C₃-C₈ cycloalkyl or aryl;

each R¹ and R² is independently selected from H, C₁-C₆ alkyl, -OH, -O-C₁-C₆ alkyl, -SH, and -S-C₁-C₆ alkyl;

each R³ is the same or different and is independently selected from halo, cyano, nitro, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar, ~~-C₀-C₆ alkyl-Het~~, -C₀-C₆ alkyl-C₃-C₇ cycloalkyl, -C₀-C₆ alkyl-CO₂R¹¹, -C₀-C₆ alkyl-C(O)SR¹¹, -C₀-C₆ alkyl-CONR¹²R¹³, -C₀-C₆ alkyl-COR¹⁴, -C₀-C₆ alkyl-NR¹²R¹³, -C₀-C₆ alkyl-SR¹¹, -C₀-C₆ alkyl-OR¹¹, -C₀-C₆ alkyl-SO₃H, -C₀-C₆ alkyl-SO₂NR¹²R¹³, -C₀-C₆ alkyl-SO₂R¹¹, -C₀-C₆ alkyl-SOR¹⁴, -C₀-C₆ alkyl-OCOR¹⁴, -C₀-C₆ alkyl-OC(O)NR¹²R¹³, -C₀-C₆ alkyl-OC(O)OR¹⁴, -C₀-C₆ alkyl-NR¹²C(O)OR¹⁴, -C₀-C₆ alkyl-NR¹²C(O)NR¹²R¹³, and -C₀-C₆ alkyl-NR¹²COR¹⁴, wherein said C₁-C₆ alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each R⁴ and R⁵ is independently H or C₁-C₄ alkyl;

R⁶ and R⁷ are each independently H or C₁-C₄ alkyl;

R⁸ and R⁹ are each independently H or C₁-C₄ alkyl;

R¹⁰ is ~~selected from~~ H, C₁-C₈ alkyl, C₃-C₈ alkenyl, C₃-C₈ alkynyl, -C₀-C₆ alkyl-Ar, ~~-C₀-C₆ alkyl-Het and or~~ -C₀-C₆ alkyl-C₃-C₇ cycloalkyl;

R¹¹ is ~~selected from~~ H, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar, ~~-C₀-C₆ alkyl-Het and or~~ -C₀-C₆ alkyl-C₃-C₇ cycloalkyl;

each R¹² and each R¹³ are independently selected from H, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar, ~~-C₀-C₆ alkyl-Het and~~ -C₀-C₆ alkyl-C₃-C₇ cycloalkyl, ~~or R¹³ and R¹⁴ together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S; and~~

R¹⁴ is ~~selected from~~ C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar, ~~-C₀-C₆ alkyl-Het and or~~ -C₀-C₆ alkyl-C₃-C₇ cycloalkyl;

provided that R¹⁰ is not H or methyl when p is 1 and R¹ and R² are each H, k is 0, n is 3 and each R⁴ and R⁵ are H, q is 1 and R⁸ and R⁹ are each H, Q is unsubstituted phenyl or 4-methoxyphenyl or 2-chloro-3-trifluoromethyl-phenyl, R⁶ and R⁷ are each H, W¹ is unsubstituted phenyl and W² is unsubstituted phenyl or unsubstituted cyclohexyl;

or a pharmaceutically acceptable salt or ~~[[solvate]]~~ hydrate thereof.

2. (Original): The compound according to claim 1, wherein p is 0 or 1.

3. (Currently amended): The compound according to ~~any of claims 1-2~~ claim 1, wherein R^1 and R^2 are each H, or one of R^1 or R^2 is H and the other of R^1 or R^2 is C_1 - C_4 alkyl or both R^1 and R^2 are C_1 - C_3 alkyl.

4. (Currently amended): The compound according to ~~any of claims 1-2~~ claim 1, wherein R^1 and R^2 are each H, or one of R^1 or R^2 is H and the other of R^1 or R^2 is methyl, ethyl, propyl, butyl, or sec-butyl, or R^1 and R^2 are both methyl or ethyl.

5. (Currently amended): The compound according to ~~any of claims 1-4~~ claim 1, wherein R^{10} is H or C_1 - C_4 alkyl.

6. (Currently amended): The compound according to ~~any of claims 1-5~~ claim 1, wherein Z is CH.

7. (Currently amended): The compound according to ~~any of claims 1-6~~ claim 1, wherein k is 0 or 1.

8. (Currently amended): The compound according to ~~any of claims 1-7~~ claim 1, wherein R^3 is selected from halo, C_1 - C_4 alkyl and C_1 - C_4 alkoxy.

9. (Currently amended): The compound according to ~~any of claims 1-8~~ claim 1, wherein n is 2-4.

10. (Currently amended): The compound according to ~~any of claims 1-9~~ claim 1, wherein n is 3.

11. (Currently amended): The compound according to ~~any of claims 1-10~~ claim 1, wherein q is 1.

12. (Currently amended): The compound according to ~~any of claims 1-11~~ claim 1, wherein R^6 , R^7 , R^8 and R^9 are each H.

13. (Currently amended): The compound according to ~~any of claims 1-12~~ claim 1, wherein Q is a substituted phenyl group containing one, two, or three substituents selected from halo, C₁-C₄ alkoxy and C₁-C₄ alkyl ~~or Q is substituted pyridyl group containing one C₁-C₄ alkyl substituent.~~

14. (Currently amended): The compound according to ~~any of claims 1-13~~ claim 1, wherein Q is a substituted phenyl group containing one, two, or three substituents selected from -F, -Cl, -CF₃, -OCH₃, and -CH(CH₃)₂, ~~or Q is 6-methyl-pyridin-2-yl.~~


15. (Currently amended): The compound according to ~~any of claims 1-14~~ claim 1, wherein Q is a 2-chloro-3-(trifluoromethyl)phenyl group.

16. (Currently amended): The compound according to ~~any of claims 1-15~~ claim 1, wherein W¹ and W² are each aryl or one of W¹ or W² is aryl and the other of W¹ or W² is cyclopentyl.

17. (Currently amended): The compound according to ~~any of claims 1-16~~ claim 1, wherein W¹ and W² are each independently selected from unsubstituted cyclopentyl, unsubstituted phenyl and mono-substituted phenyl, where the phenyl is substituted by halo.

18. (Currently amended): The compound according to ~~any of claims 1-17~~ claim 1, wherein W¹ and W² are both unsubstituted phenyl, or one of W¹ or W² is unsubstituted phenyl and the other of W¹ or W² is cyclopentyl, or W¹ and W² are both fluoro-substituted phenyl or one of W¹ or W² is unsubstituted phenyl and the other of W¹ or W² is chloro-substituted phenyl.

19. (Currently amended): A compound of Formula II:



wherein:

Z is CH or N;

Q is phenyl or monocyclic Het; wherein said phenyl and monocyclic Het are is optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₄ alkyl-CO₂R¹¹, -C₀-C₄ alkyl-C(O)SR¹¹, -C₀-C₄ alkyl-CONR¹²R¹³, -C₀-C₄ alkyl-COR¹⁴, -C₀-C₄ alkyl-NR¹²R¹³, -C₀-C₄ alkyl-SR¹¹, -C₀-C₄ alkyl-OR¹¹, -C₀-C₄ alkyl-SO₃H, -C₀-C₄ alkyl-SO₂NR¹²R¹³, -C₀-C₄ alkyl-SO₂R¹¹, -C₀-C₄ alkyl-SOR¹⁴, -C₀-C₄ alkyl-OCOR¹⁴, -C₀-C₄ alkyl-OC(O)NR¹²R¹³, -C₀-C₄ alkyl-OC(O)OR¹⁴, -C₀-C₄ alkyl-NR¹²C(O)OR¹⁴, -C₀-C₄ alkyl-NR¹²C(O)NR¹²R¹³, and -C₀-C₄ alkyl-NR¹²COR¹⁴, where said C₁-C₆ alkyl is optionally unsubstituted or substituted by one or more halo substituents,

p is 0-4;

k is 0, 1 or 2;

n is 2-4;

q is 0 or 1;

W¹ and W² are each independently C₃-C₆ cycloalkyl or aryl;

each R¹ and R² is independently selected from H, C₁-C₄ alkyl, -OH, -O-C₁-C₄ alkyl, -SH, and -S-C₁-C₄ alkyl;

each R³ is the same or different and is independently selected from halo, cyano, C₁-C₆ alkyl, -C₀-C₄ alkyl-NR¹²R¹³, -C₀-C₄ alkyl-OR¹¹, -C₀-C₄ alkyl-SO₂NR¹²R¹³, and -C₀-C₄ alkyl-CO₂H, wherein said C₁-C₆ alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each R⁴ and R⁵ is independently H or C₁-C₄ alkyl;

R⁶ and R⁷ are each independently H or C₁-C₄ alkyl;

R⁸ and R⁹ are each independently H or C₁-C₄ alkyl;

R¹⁰ is ~~selected from~~ H, C₁-C₆ alkyl, -C₀-C₄ alkyl-Ar, ~~-C₀-C₄ alkyl-Het and or~~ -C₀-C₄ alkyl-C₃-C₆ cycloalkyl;

R¹¹ is ~~selected from~~ H, C₁-C₆ alkyl, -C₀-C₄ alkyl-Ar, ~~-C₀-C₄ alkyl-Het and or~~ -C₀-C₄ alkyl-C₃-C₇ cycloalkyl;

each R¹² and each R¹³ are independently selected from H, C₁-C₆ alkyl, -C₀-C₄ alkyl-Ar, ~~-C₀-C₄ alkyl-Het and~~ -C₀-C₄ alkyl-C₃-C₇ cycloalkyl, ~~or R¹² and R¹³ together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S; and~~

R^{14} is selected from C_1 - C_6 alkyl, $-C_0$ - C_4 alkyl-Ar, ~~$-C_0$ - C_4 alkyl-Het~~ and or
 $-C_0$ - C_4 alkyl- C_3 - C_7 cycloalkyl;

provided that R^{10} is not H or methyl when p is 1 and R^1 and R^2 are each H, k is 0, n is 3 and each R^4 and R^5 are H, q is 1 and R^8 and R^9 are each H, Q is unsubstituted phenyl or 4-methoxyphenyl or 2-chloro-3-trifluoromethyl-phenyl, R^6 and R^7 are each H, W^1 is unsubstituted phenyl and W^2 is unsubstituted phenyl or unsubstituted cyclohexyl;
or a pharmaceutically acceptable salt or ~~[[solvate]]~~ hydrate thereof.

20. (Currently amended): The compound according to claim 1 ~~or 19~~, wherein R^4 , R^5 , R^6 , R^7 , R^8 and R^9 are each H; at least one of R^1 or R^2 is methyl, ethyl, propyl butyl or sec-butyl or both of R^1 and R^2 are methyl or ethyl; R^{10} is H or methyl; Q is 2-chloro-3-(trifluoromethyl)phenyl; W^1 and W^2 are both unsubstituted phenyl, or one of W^1 or W^2 is unsubstituted phenyl and the other of W^1 or W^2 is cyclopentyl, or W^1 and W^2 are both fluoro-substituted phenyl or one of W^1 or W^2 is unsubstituted phenyl and the other of W^1 or W^2 is chloro-substituted phenyl; Z is CH; p is 0, 1 or 2; n is 3; q is 1; k is 0 or 1 and R^3 is Cl, Br or methyl; or a pharmaceutically acceptable salt or ~~[[solvate]]~~ hydrate thereof.

21. (Currently amended): The compound according to claim 1 ~~or 19~~, wherein R^6 , R^7 , R^8 and R^9 are each H; R^1 and R^2 are each independently H or methyl; at least one R^4 or R^5 is methyl; R^{10} is H or methyl; Q is a substituted phenyl group containing one, two, or three substituents selected from -F, -Cl, -CF₃, -OCH₃, and -CH(CH₃)₂; W^1 and W^2 are unsubstituted phenyl; Z is CH; p is 1; n is 3; q is 1; and k is 0; or a pharmaceutically acceptable salt or ~~[[solvate]]~~ hydrate thereof.

22. (Currently amended): ~~[[The]]~~ A compound ~~according to claims 1 or 19~~, selected from:

(*R*)-2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-2-methyl-propoxy}-phenyl)acetic acid methyl ester;

(*R*)-2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-2-methyl-propoxy}-phenyl)acetic acid;

(*S*)-2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-2-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-1-methyl-propoxy}-phenyl)acetic acid methyl ester;

(*R*)-2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-1-methyl-propoxy}-phenyl)acetic acid;

(*S*)-2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-1-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-3-methyl-propoxy}-phenyl)acetic acid;

(*S*)-2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-3-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[2-fluoro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-2-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[3-(trifluoromethyl)-4-fluoro-benzyl](2,2-diphenylethyl)amino]-2-methyl-propoxy}-phenyl)acetic acid;

~~(*R*)-2-(3-{3-[[6-methyl-pyridin-2-ylmethyl](2,2-diphenylethyl)amino]-2-methyl-propoxy}-phenyl)acetic acid;~~

(*R*)-2-(3-{3-[[2,4-dimethoxy-benzyl](2,2-diphenylethyl)amino]-2-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[4-methoxy-benzyl](2,2-diphenylethyl)amino]-2-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[2-fluoro-4-methoxy-benzyl](2,2-diphenylethyl)amino]-2-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[3-fluoro-4-methoxy-benzyl](2,2-diphenylethyl)amino]-2-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[2,4-dimethoxybenzyl](2,2-diphenylethyl)amino]-1-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[4-methoxybenzyl](2,2-diphenylethyl)amino]-1-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[2-fluoro-4-methoxybenzyl](2,2-diphenylethyl)amino]-1-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[3-trifluoromethylbenzyl](2,2-diphenylethyl)amino]-1-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[2-fluoro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-1-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[3-(trifluoromethyl)-4-fluoro-benzyl](2,2-diphenylethyl)amino]-1-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[3-fluoro-4-methoxybenzyl](2,2-diphenylethyl)amino]-1-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[2-chlorobenzyl](2,2-diphenylethyl)amino]-3-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[3-trifluoromethylbenzyl](2,2-diphenylethyl)amino]-3-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[2-fluoro-(3-trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-3-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[3-trifluoromethyl-4-fluoro-benzyl](2,2-diphenylethyl)amino]-3-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[2,4-dimethoxybenzyl](2,2-diphenylethyl)amino]-3-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[4-methoxybenzyl](2,2-diphenylethyl)amino]-3-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[2-fluoro-4-methoxybenzyl](2,2-diphenylethyl)amino]-3-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[2-chloro-3,4-dimethoxybenzyl](2,2-diphenylethyl)amino]-3-methyl-propoxy}-phenyl)acetic acid;

(*R*)-2-(3-{3-[[3-fluoro-4-methoxybenzyl](2,2-diphenylethyl)amino]-3-methyl-propoxy}-phenyl)acetic acid;

(3-{(*R*)-[(2,2-diphenyl-ethyl)-(4-isopropyl-benzyl)-amino]-methyl-propoxy}-phenyl)-acetic acid;

3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-propoxy}-4-methyl-benzoic acid;

(3-{3-[[2,2-(bis-(4-fluoro-phenyl)-ethyl)-(2-chloro-3-(trifluoromethyl)-benzyl)-amino]-propoxy}-phenyl)-acetic acid;

(3-{3-[[2,2-(bis-(3-fluoro-phenyl)-ethyl)-(2-chloro-3-(trifluoromethyl)-benzyl)-amino]-propoxy}-phenyl)-acetic acid;

rac-(3-{3-[[2-phenyl-2-(*o*-chloro-phenyl)-ethyl]-(2-chloro-3-(trifluoromethyl)-benzyl)-amino]-propoxy}-phenyl)-acetic acid;

2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-butyric acid;

2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-pentanoic acid;

2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-hexanoic acid;

2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-4-methyl-pentanoic acid;

2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-2-ethyl-butyric acid methyl ester;

2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-2-ethyl-butyric acid;

2-(3-{(R)-3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-butoxy}-phenyl)-2-methyl-propionic acid;

3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-benzoic acid methyl ester;

3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-benzoic acid;

2-bromo-5-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-benzoic acid;

(2-bromo-5-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-acetic acid;

N-(2-phenyl-2-cyclopentylethyl)-*N*-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine;

N-(2,2-diphenylethyl)-*N*-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxyphenoxy)propylamine;

N-(2,2-diphenylethyl)-*N*-(2-chloro-3-trifluoromethylbenzyl)-2,2-dimethyl-3-(3-aminopropoxy)phenylpropionic acid;

(3-chloro-4-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-acetic acid methyl ester;

(3-chloro-4-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-acetic acid;

2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-2-methyl-propionic acid; and

2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-propionic acid;

~~and a stereoisomer, a stereoisomeric mixture or racemate thereof and~~ or a pharmaceutically acceptable salt or ~~[[solvate]]~~ hydrate thereof.

23. (Currently amended): A pharmaceutical composition comprising a compound according to ~~any one of claims 1-22~~ claim 1 and a pharmaceutically acceptable carrier or diluent.

24-45. (Cancelled).

46. (Withdrawn): A method for increasing reverse cholesterol transport, said method comprising administering a therapeutically effective amount of ~~[[a]]~~ the compound according to claim 1.

Claims 47-55. (Cancelled).

56. (Withdrawn): A compound according to claim 1 wherein at least one of R⁴, R⁵, R⁶, R⁷, R⁸ or R⁹ is defined as follows:

wherein at least one R⁴ or R⁵ is C₁-C₄ alkyl; or

at least one of R⁶ or R⁷ is C₁-C₄ alkyl; or

both of R⁸ or R⁹ are independently C₁-C₄ alkyl.

57. (Withdrawn): A compound according to claim 1 wherein at least one R⁴ or R⁵ is methyl.

58. (Currently amended, Withdrawn): A compound according to claim 1 wherein:

any one of R⁴ or R⁵ is not H or

any one of R⁶ or R⁷ is not H or

Application No.: 10/508,893

Group Art Unit: 1625

R^8 and R^9 are each C_1 - C_4 alkyl when

Z is CH or CR^3 and k is 0-4 ~~or Z is N and k is 0-3;~~

p is 0-8;

n is 2-8;

q is 0 or 1;

Q is ~~selected from~~ optionally unsubstituted or substituted C_3 - C_8 cycloalkyl[[,]] or
phenyl ~~and mono-cyclic Het;~~

W^1 and W^2 are each independently optionally unsubstituted or substituted
 C_3 - C_8 cycloalkyl or aryl;

each R^1 and R^2 is independently selected from H , C_1 - C_6 alkyl, $-OH$, $-O$ - C_1 - C_6 alkyl,
 $-SH$, and $-S$ - C_1 - C_6 alkyl;

each R^3 is the same or different and is independently selected from halo, cyano, nitro,
 $-CONR^{12}R^{13}$, $-COR^{14}$, $-SR^{11}$, $-SO_2R^{11}$, $-SOR^{14}$, $-OCOR^{14}$ and optionally unsubstituted or
substituted C_1 - C_6 alkyl, C_3 - C_6 alkenyl, ~~5-6 membered Het~~, $-C_0$ - C_6 alkyl- CO_2R^{11} , or
 $-C_0$ - C_6 alkyl- $NR^{12}R^{13}$.